Citius Pharmaceuticals

1D
1W
1M
3M
1Y
5Y

Why Robinhood?

Robinhood gives you the tools you need to put your money in motion. You can buy or sell CTXR and other ETFs, options, and stocks.

About CTXR

Citius Pharmaceuticals, Inc. is a biopharmaceutical company dedicated to the development and commercialization of critical care products, with a focus on anti-infectives in adjunct cancer care, unique prescription products, and stem cell therapy. It is currently advancing four proprietary product candidates: Mino-Lok, which is an antibiotic lock solution used to treat patients with catheter-related bloodstream infections, Mino-Wrap, a liquifying gel-based wrap for reduction of tissue expander infections following breast reconstructive surgeries, Halo-Lido, a corticosteroid-lidocaine topical formulation that is intended to provide anti-inflammatory and anesthetic relief to people suffering from hemorrhoids, NoveCite, a mesenchymal stem cell therapy for the treatment of acute respiratory distress syndrome, and I/ONTAK, a protein for the treatment of patients with persistent or recurrent cutaneous T-cell lymphoma (CTCL). 

CEO
Leonard L. Mazur
CEOLeonard L. Mazur
Employees
15
Employees15
Headquarters
Cranford, New Jersey
HeadquartersCranford, New Jersey
Founded
2007
Founded2007
Employees
15
Employees15

CTXR Key Statistics

Market cap
169.51M
Market cap169.51M
Price-Earnings ratio
Price-Earnings ratio
Dividend yield
Dividend yield
Average volume
457.45K
Average volume457.45K
High today
High today
Low today
Low today
Open price
$1.16
Open price$1.16
Volume
0.00
Volume0.00
52 Week high
$2.01
52 Week high$2.01
52 Week low
$0.8306
52 Week low$0.8306

CTXR Earnings

-$0.06
-$0.04
-$0.02
$0.00
Q2 FY21
Q3 FY21
Q4 FY21
Q1 FY22
Q2 FY22
Q3 FY22
Q4 FY22
Estimated
per share
Estimated per share
Actual
Expected Dec 14, After Hours
ActualExpected Dec 14, After Hours
All investments involve risks, including the loss of principal. Securities trading offered through Robinhood Financial LLC, Member SIPC and a registered broker-dealer.